Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors (MICRO-VAR)
Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors : a Retrospective Study
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology.
This study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT/MRI at 6-12 weeks, accounting for expected tissue shrinkage.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Valérie LAURENT, MD-PhD
- Phone Number: 33383157823
- Email: v.laurent@chru-nancy.fr
Study Contact Backup
- Name: Astrée LEMORE, MD
- Phone Number: 33383157823
- Email: a.lemore@chru-nancy.fr
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, F54511
- Recruiting
- CHRU Nancy
-
Contact:
- Astrée LEMORE
- Email: a.lemore@chru-nancy.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients
- Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance
- Adult treated for one or more liver lesions
- Patients with available follow-up imaging
Exclusion Criteria:
- Two treatment cycles on the same lesion during the same session.
- Reoperation on the same lesion.
- Planned volume not available (no manufacturer data, not specified in the surgical report).
- No control imaging injected between 1 and 4 months post-procedure.
- Final ablation volume not measurable (e.g., artifacts, no injection on MRI).
- No definitive diagnosis of the nature of the tumor on imaging and no histology available.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Small final ablation axis measured on the post-procedure imaging modality considered to be the most reliable.
Time Frame: 12 weeks
|
The final short axis will preferably be measured (in mm) on MRI at 6-12 weeks.
If inter-patient variability in volume shrinkage exceeds 5%, the modality with the lowest relative variability (usually the immediate CT scan) will be used as the reference for estimating the final volume.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025PI_230
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasm
-
NCT02886104RecruitingSecondary Malignant Neoplasm of Liver
-
NCT03889093TerminatedHepatocellular Carcinoma | Secondary Malignant Neoplasm of Liver
-
NCT02843802CompletedSecondary Malignant Neoplasm of Liver
-
NCT02070549CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm
-
NCT02820194TerminatedSecondary Malignant Neoplasm of Liver
-
NCT02391207CompletedSecondary Malignant Neoplasm of Liver
-
NCT01457599CompletedSecondary Malignant Neoplasm of Liver
-
NCT00510627WithdrawnLiver Neoplasm | Metastatic Liver Cancer | Secondary Liver Cancer
-
NCT04010071RecruitingHepatobiliary Neoplasm | Liver Neoplasm | Biliary Tract Neoplasms
-
NCT02758977UnknownLiver Diseases | Liver Neoplasms | Hepatectomy | Surgery | Secondary Malignant Neoplasm of Liver | Colon Cancer Liver Metastases | Malignant Neoplasm of Large Intestine Metastatic to Liver